Proteomics Market Scope And Analysis

Report Code : TIPHE100001115
Category : Biotechnology

No. of Pages : 150

Buy Now

Proteomics Market Analysis and Scope (2021 to 2022)

Buy Now

Proteomics Market Report Scope

Report Attribute	Details
Market size in 2022	US$ 27.07 Billion
Market Size by 2030	US$ 75.03 Billion
Global CAGR (2022 - 2030)	13.6%
Historical Data	2020-2022
Forecast period	2022-2030
Segments Covered	By Product & Service Instrumentation Technologies Reagents & Consumables Software & Services By Application Clinical Diagnostics Drug Discovery & Development By End User Pharmaceutical & Biotechnology Companies Research & Clinical Laboratories Hospitals
Regions and Countries Covered	North America US Canada Mexico Europe UK Germany France Russia Italy Rest of Europe Asia-Pacific China India Japan Australia Rest of Asia-Pacific South and Central America Brazil Argentina Rest of South and Central America Middle East and Africa South Africa Saudi Arabia UAE Rest of Middle East and Africa
Market leaders and key company profiles	Proteome Sciences Biognosys Creative Proteomics Shantani Olink SomaLogic Operating Co Inc QUANTUM SI INCORPORATED Proteomics International Promise Proteomics

Key Player Analysis:

Proteome Sciences; Biognosys; Creative Proteomics; Shantani; Olink; SomaLogic Operating Co., Inc.; QUANTUM-SI INCORPORATED; Proteomics International; Promise Proteomics; SCIEX; Illumina, Inc.; and Thermo Fisher Scientific Inc are among the key players profiled in the proteomics market report.

Recent Developments:

Companies operating in the proteomics market adopt mergers and acquisitions as key growth strategies. As per company press releases, a few recent market developments are listed below:

In June 2022, SomaLogic and Illumina, Inc. announced a joint development agreement in which companies will utilize the SomaScan Proteomics Assay on Illumina's current and future high-throughput next-generation sequencing (NGS) platforms. The partnership accelerated next-generation sequencing in the proteomics market's fast-growing, ultra-high throughput workflow.
In May 2022, Proteomics International Laboratories Ltd received US$ 13,516 in funding to enable the production of its PromarkerD clinical diagnostic in Australia, the world's first diagnostic, predictive test for diabetes-related kidney disease. The program aims to foster new health innovations, advance discoveries toward proof-of-concept and commercialization that address important health problems and maximize entrepreneurial and idea potential.